PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap's lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.
Industry, Sector and Symbol
Stock Exchange CVE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCVE:GAP
CUSIPN/A
WebN/A
Phone+1-613-2873118
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market CapC$0.00
PharmaGap (CVE:GAP) Frequently Asked Questions
What is PharmaGap's stock symbol?
PharmaGap trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GAP."
Has PharmaGap been receiving favorable news coverage?
Media headlines about GAP stock have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PharmaGap earned a news impact score of 0.07 on Accern's scale. They also gave news coverage about the company an impact score of 47.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for PharmaGap.
How do I buy shares of PharmaGap?
Shares of GAP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How can I contact PharmaGap?
PharmaGap's mailing address is 1000 Innovation Drive, Suite 400, OTTAWA, ON K2K 2K7, Canada. The company can be reached via phone at +1-613-2873118.
MarketBeat Community Rating for PharmaGap (CVE GAP)
MarketBeat's community ratings are surveys of what our community members think about PharmaGap and other stocks. Vote "Outperform" if you believe GAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
